Prodrugs - Current development and applications in ocular drug delivery

Chauhan, Akshita; Khan, Tabassum

doi:10.1016/j.jddst.2021.102836

Cited by 3 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The active compound has carboxyl or hydroxyl groups that are esterified to give a lipophilic substance. The corneal epithelium, esterase, is 2.5-fold more as compared to the endothelium and stroma [86]. An example is the nepafenac prodrug, used for inflammation and the pain associated with cataract surgery [87].…”

Section: Strategies For Enhancing Ocular Drug Delivery Systemmentioning

confidence: 99%

Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems

et al. 2021

View full text Add to dashboard Cite

One of the major impediments to drug development is low aqueous solubility and thus poor bioavailability, which leads to insufficient clinical utility. Around 70–80% of drugs in the discovery pipeline are suffering from poor aqueous solubility and poor bioavailability, which is a major challenge when one has to develop an ocular drug delivery system. The outer lipid layer, pre-corneal, dynamic, and static ocular barriers limit drug availability to the targeted ocular tissues. Biopharmaceutical Classification System (BCS) class II drugs with adequate permeability and limited or no aqueous solubility have been extensively studied for various polymer-based solubility enhancement approaches. The hydrophilic nature of cellulosic polymers and their tunable properties make them the polymers of choice in various solubility-enhancement techniques. This review focuses on various cellulose derivatives, specifically, their role, current status and novel modified cellulosic polymers for enhancing the bioavailability of BCS class II drugs in ocular drug delivery systems.

show abstract

Section: Strategies For Enhancing Ocular Drug Delivery Systemmentioning

confidence: 99%